Results 91 to 100 of about 5,502 (160)

Cereblon as a gateway for pharmacologically induced teratogenicity

, 2015
In the public perception, thalidomide mainly evokes children with stunted limbs. Less known is its ongoing importance for treating multiple myeloma and leprosy. Interest in its further pharmacological development thus remains high, but is hindered by the
Boichenko, I. ; https://orcid.org/, Zhu, H. ; https://orcid.org/, Lupas, A. ; https://orcid.org/, Coles, M. ; https://orcid.org/, Zanini, F. ; https://orcid.org/, Hartmann, M. ; https://orcid.org/, Korycinski, M., Hernandez Alvarez, B. ; https://orcid.org/   +7 more
core  

Investigation of the anti-cancer drugs imatinib and thalidomide using analytical spectroscopy (FT-IR, UV-Vis) and molecular docking simulations

Results in Chemistry
Cancer is one of the most fatal diseases in modern civilisation, accounting for a significant number of deaths each year. The continued investigation of the medical effects of cancer is still an important and fascinating field of study.
P. Venkata Ramana, Y. Rama Krishna, Prasadarao Bobbili, K. Venkata Prasad, K. Chandra Mouli   +4 more
doaj   +1 more source

Oligo-PROTAC strategy for cell-selective and targeted degradation of activated STAT3

Molecular Therapy: Nucleic Acids
Decoy oligodeoxynucleotides (ODNs) allow targeting undruggable transcription factors, such as STAT3, but their limited potency and lack of delivery methods hampered translation.
Jeremy Hall, Zhuoran Zhang, Supriyo Bhattacharya, Dongfang Wang, Marice Alcantara, Yong Liang, Piotr Swiderski, Stephen Forman, Larry Kwak, Nagarajan Vaidehi, Marcin Kortylewski   +10 more
doaj   +1 more source

Mezigdomide—A Novel Cereblon E3 Ligase Modulator under Investigation in Relapsed/Refractory Multiple Myeloma

Mezigomide is an oral cereblon E3 ligase modulator (CELMoD) that is under clinical investigation in patients with relapsed/refractory (RR) multiple myeloma (MM).
Monique A. Hartley-Brown, Shonali Midha, Clifton C. Mo, Paul G. Richardson, Omar Nadeem, Jacob P. Laubach   +5 more
core   +1 more source

Design, Synthesis, Biological Studies and Putative Binding Mode of Novel Benzotriazolothalidomide Derivatives as Cereblon Ligands. [PDF]

Chem Biol Drug Des
Ganguly P, Kundu M, Sarkar T, Dcosta G, Banerjee K, Banerjee R, Hajra AK, Sahabuddin S, Basu S, Das A, Das S, Barik R, Ali MA.   +12 more
europepmc   +1 more source

In Silico Analysis of Enantioselective Binding of Pomalidomide Targets for Multiple Myeloma. [PDF]

Chirality
Vardhan G, Kumar V, Kumar A, Handu S, Dhamija P.   +4 more
europepmc   +1 more source

Discovery of JH-XIII-05-01, a First-in-Class Dual IRAK1/IRAK4 Degrader for MYD88 Mutant Lymphomas. [PDF]

ACS Med Chem Lett
Hatcher JM, Liu S, Liu X, Kofides A, Canning AG, Pizzarella D, Tsakmaklis N, Guerrera ML, Patterson CJ, Guijosa A, Gokhale P, Hunter ZR, Sarosiek SR, Castillo JJ, Wang J, Buhrlage SJ, Treon SP.   +16 more
europepmc   +1 more source

Development of Cereblon (CRBN) as an early prognostic biomarker in Paediatric Sepsis: a Prospective Observational Study Protocol. [PDF]

BMJ Open
Mishra N, Gupta A, Gupta R, Kumar M, Shukla A.   +4 more
europepmc   +1 more source

Two Mechanisms One Molecule: Developing a 'Truly' Bifunctional Degrader Targeting Rpn13 and CRBN. [PDF]

J Am Chem Soc
Loy CA, Vinogradsky SE, Trader DJ.
europepmc   +1 more source

Vepdegestrant for ESR1-mutated breast cancer. [PDF]

Trends Pharmacol Sci
MacLeod RS, Liu CJ.
europepmc   +1 more source